重组改构人肿瘤坏死因子控制肺癌恶性胸腔积液的临床疗效观察.docVIP

精品论文 参考文献 重组改构人肿瘤坏死因子控制肺癌恶性胸腔积液的临床疗效观察 （厦门大学附属第一医院肺科 福建 厦门 361003） 【摘要】 目的：分析重组改构人肿瘤坏死因子与顺铂在控制肺癌合并恶性胸腔积液的临床疗效及毒副反应。方法：分析我院于2013年6月至2015年1月收治68例肺癌恶性胸腔积液患者，随机分为两组，每组34名，观察组采用生理盐水30ml+重组改构人肿瘤坏死因子400万IU胸腔内注入，对照组采用生理盐水30ml+顺铂60mg胸腔内注入；两组在注药前均先予胸腔内注入生理盐水10ml+地塞米松磷酸钠注射液5mg；1周注药2次，休息1周后，再次注药1周为1疗程，8周后评价疗效。结果：观察组中无效2例，有效32例，治疗过程中出现发热3例，胸痛1例，无出现恶心呕吐及纳差症状，发热及胸痛症状无需特殊处理，均可自行缓解；对照组中无效11例，有效23例，治疗过程中出现发热0例，胸痛10例，恶心呕吐及纳差症状6例，其中4例需给予止吐对症处理。结论：肺癌合并恶性胸腔积液患者，在给予胸腔内注药控制恶性胸腔积液时，重组改构人肿瘤坏死因子在疗效方面明显优于顺铂，其毒副反应明显较顺铂为低，能明显减轻晚期肺癌患者的痛苦，提高生活质量。 【关键词】 晚期肺癌；恶性胸腔积液；重组改构人肿瘤坏死因子；顺铂 【中图分类号】R730.5 【文献标识码】A 【文章编号】2095-1752（2015）31-0032-02 Clinical effect of recombinant human tumor necrosis factor in controlling malignant pleural effusion of lung cancer Su We-ming，Wu Dinghui，Lan Guocui.. Dempartment of Pulmonary Medicine, the First Hospital of Xiamen University, Fujian Province，Xiamen 361003,China 【Abstract】Objective To analyze the clinical efficacy and toxicity of recombinant human tumor necrosis factor and cisplatin in controlling lung cancer with malignant pleural effusion. Methods From June 2013 to January 2015, 68 patients with malignant pleural effusion were randomly divided into two groups, 34 patients in each group. The control group was treated with normal saline 30ml+ 10ml+ injection, the control group was treated with normal saline 5mg cisplatin 60mg. 1 weeks, 2 weeks, 1 weeks, 8 weeks, 1 weeks after injection, two weeks after 1 weeks.Results Observation group in 2 cases were invalid, effective in 32 cases, the treatment of fever in 3 cases, 1 cases of chest pain, nausea, vomiting and anorexia symptoms appeared, fever and chest pain without special treatment is needed, can alleviate by oneself; in the control group 11 cases ineffective, the effective in 23 cases, in the course of treatment appear fever cases, 10 cases of chest pain, nausea, vomiting and anorexia symptoms in 6 cases, including 4 cases